A leading provider of
innovative DNA Screening solutions
IGH/MAF Translocation, Dual Fusion LPH029
The translocation t(14;16) (q32.3;q22) involving c-MAF and IGH is present in 25% of myeloma cell lines and in 2-6% of primary Multiple Myeloma samples. A recent gene expression profiling of myeloma cell lines revealed that c-MAF transactivated cyclin D2 (a promoter of cell cycle progression), thus enhancing proliferation of myeloma cells. WWOX, a putative tumour suppressor gene is contained within the breakpoint region of the c-MAF-IGH translocation, is a frequent target for loss of heterozygosity and chromosomal rearrangements in ovarian, breast, hepatocellular, prostate carcinomas and other neoplasias.
IGH/MAF Translocation, Dual Fusion
Cat. No. LPH 029-S (5 tests)
Cat. No. LPH 029 (10 tests)
This webpage could contain information on product details or information not valid in your country or region. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in the country of your origin. If you are a resident of a country other than those to which this site is directed, contact your local Cytocell distributor to obtain the appropriate product information for your country of residence.
Developed &produced in the UK